Career history of Ralf H. Rosskamp
Former positions of Ralf H. Rosskamp
Companies | Position | Start | End |
---|---|---|---|
DICERNA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2017-06-14 | 2020-09-07 |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Director/Board Member | 2016-04-30 | 2017-08-30 |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | Chief Tech/Sci/R&D Officer | 2014-12-31 | 2017-05-22 |
NPS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2013-06-30 | 2015-04-30 |
IKARIA, INC. | Chief Tech/Sci/R&D Officer | 2010-05-19 | 2010-06-15 |
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Chief Tech/Sci/R&D Officer | 2003-09-30 | 2006-12-31 |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | 2003-08-31 | 2003-08-31 |
Global Therapeutics, Inc. | Corporate Officer/Principal | 2002-12-31 | 2002-12-31 |
Hoechst AG
Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Corporate Officer/Principal | 1989-12-31 | 1995-12-31 |
░░░░░░░░░░ ░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Ralf H. Rosskamp
University of Bonn | Doctorate Degree |
Statistics
International
United States | 7 |
Germany | 3 |
United Kingdom | 3 |
Operational
Corporate Officer/Principal | 6 |
Chief Tech/Sci/R&D Officer | 4 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 8 |
Process Industries | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 10 |
---|---|
NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
KOS Pharmaceuticals, Inc.
KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Health Technology |
Hoechst AG
Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Summit Therapeutics Ltd.
Summit Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Summit Therapeutics Ltd. operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Ikaria, Inc.
Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Global Therapeutics, Inc. | Commercial Services |
Hoechst Pharmaceuticals Ltd. |
- Stock Market
- Insiders
- Ralf H. Rosskamp
- Experience